Katy Marshall

Katy Marshall

Articles by Katy Marshall

Katy MarshallColorectal Cancer | September 4, 2024
There is little research on the efficacy of adding oxaliplatin to treat older patients with the disease.
Read More
Katy MarshallGIST | August 28, 2024
Researchers specifically used data from the SEER-22 and SEER-17 registries.
Katy MarshallColorectal Cancer | August 21, 2024
The systematic review included data from 12 randomized controlled trials, 2 systematic reviews, and 1 nonrandomized study.
Katy MarshallGI Cancer | August 16, 2024
GNAS-mutated tumors displayed C-to-T mutation-high, aneuploidy-low molecular profile.
Katy MarshallGEP-NETs | August 14, 2024
Cabozantinib can be used for patients with pNETs or epNETs.
Katy MarshallColorectal Cancer | August 13, 2024
Investigators calculated the C-for-benefit to evaluate evidence for HTE.
Katy MarshallGastroesophageal Cancer | August 7, 2024
Researchers noted that CIPN was negatively connected to HRQOL across all therapy groups.
Katy MarshallGastric Cancer | August 2, 2024
Currently, there is little research on the comparative accuracy of mpMRI versus DECT.
Katy MarshallUnresectable HCC | August 1, 2024
The study’s primary end point was overall survival in the inverse probability of treatment weighting.
Katy MarshallGastroesophageal Cancer | July 30, 2024
The study compared neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy.
Katy MarshallGIST | July 24, 2024
The AI model used predictors of recurrence and duration imatinib treatment to determine recurrence risk.
Katy MarshallBile Duct Cancer | July 22, 2024
Participants received pemigatinib 13.5 mg once per day for 21-day cycles with 2 weeks on and 1 week off.
Katy MarshallGastric Cancer | July 18, 2024
Researchers reported that a buildup of lactate was most notable in chemotherapy-resistant cancer tissues.
Katy MarshallUnresectable HCC | July 18, 2024
Median OS was 9.1 months for patients with CP-B7 and 4.7 months for those with CP-B8-C12.
Katy MarshallUnresectable HCC | July 12, 2024
The study investigated the Single Tremelimumab Regular Interval Durvalumab regimen.
Katy MarshallPancreatic Cancer | July 11, 2024
Research has demonstrated that DC-based immunotherapy resulted in T-cell responses against pancreatic cancer antigens.
Katy MarshallColorectal Cancer | July 10, 2024
The potential uses of bexarotene, a retinoid, for patients with colon cancer have not been adequately explored.
Katy MarshallGEP-NETs | July 4, 2024
While GEP-NETs are often torpid, the incidence of patients with GEP-NETs has increased over the last few years.
Katy MarshallBile Duct Cancer | July 3, 2024
The study's primary end point was overall survival.
Katy MarshallColorectal Cancer | July 2, 2024
The effects of targeted therapies are deterred by a rapid emergence of resistance.